SGLT2 inhibitor has been shown to inhibit glucose uptake by SGLT2-expressing human liver cancer cells (Huh7 and HepG2) at clinically comparable doses and in a dose-dependent manner, reduce intracellular adenosine triphosphate (ATP) levels, induce cell apoptosis, and indirectly suppress tumor angiogenesis [128]. Here, SLC5A2 is linked to liver cancer.